FTLD Treatment: Current Practice and Future Possibilities

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2021 Jan 12

PMID 33433882

Citations 5

Authors

Peter A Ljubenkov

Adam L Boxer

Affiliations

Soon will be listed here.

Abstract

While behavioral variant frontotemporal dementia (bvFTD) and primary progressive aphasia (PPA) remain unrelenting and universally fatal conditions, there is a framework for supportive treatment in patients diagnosed with these frontotemporal dementia (FTD) syndromes and the larger spectrum of clinical syndromes associated with frontotemporal lobar degeneration (FTLD) pathology on autopsy. A managing physician has an important role in weighing therapeutic options, organizing caregiver support, and framing long-term expectations for patients and caregivers. Additionally, a dedicated neurologist may assist patients and caregivers in navigating a growing range of FTD research, including exciting opportunities in clinical therapeutic trials. This chapter will review current therapeutic options for patients with bvFTD and PPA and detail the landscape of potential new disease-modifying therapies targeting the pathophysiology or FTLD.

Citing Articles

Communication Bridge-2 randomized controlled trial: Recruitment and baseline features.

Rogalski E, Bona M, Esparza M, Mooney A, Fried-Oken M, Rademaker A Alzheimers Dement. 2024; 21(1):e14168.

PMID: 39588869 PMC: 11771146. DOI: 10.1002/alz.14168.

Behavioral variant frontotemporal dementia associated with GRN and ErbB4 gene mutations: a case report and literature review.

Cai Y, Peng Z, He Q, Sun P BMC Med Genomics. 2024; 17(1):43.

PMID: 38291418 PMC: 10829211. DOI: 10.1186/s12920-024-01819-5.

Behavioral Treatment for Speech and Language in Primary Progressive Aphasia and Primary Progressive Apraxia of Speech: A Systematic Review.

Wauters L, Croot K, Dial H, Duffy J, Grasso S, Kim E Neuropsychol Rev. 2023; 34(3):882-923.

PMID: 37792075 PMC: 11473583. DOI: 10.1007/s11065-023-09607-1.

Advances in the Diagnosis and Management of Psychotic Symptoms in Neurodegenerative Diseases: A Narrative Review.

Seritan A J Geriatr Psychiatry Neurol. 2023; 36(6):435-460.

PMID: 36941085 PMC: 10578041. DOI: 10.1177/08919887231164357.

Knowledge and Attitudes for the Management of Behavioral Variant of Frontotemporal Dementia.

Castro-Suarez S, Guevara-Silva E, Caparo-Zamalloa C, Osorio-Marcatinco V, Meza-Vega M, Miller B Front Neurol. 2022; 12:786448.

PMID: 35087469 PMC: 8787358. DOI: 10.3389/fneur.2021.786448.

References

Talerico K, Evans L . Responding to safety issues in frontotemporal dementias. Neurology. 2001; 56(11 Suppl 4):S52-5. DOI: 10.1212/wnl.56.suppl_4.s52. View

Gomez-Tortosa E, Rigual R, Prieto-Jurczynska C, Mahillo-Fernandez I, Guerrero-Lopez R, Perez-Perez J . Behavioral Evolution of Progressive Semantic Aphasia in Comparison with Nonfluent Aphasia. Dement Geriatr Cogn Disord. 2015; 41(1-2):1-8. DOI: 10.1159/000439521. View

Hoglinger G, Respondek G, Stamelou M, Kurz C, Josephs K, Lang A . Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017; 32(6):853-864. PMC: 5516529. DOI: 10.1002/mds.26987. View

Lee S, Rabinovici G, Mayo M, Wilson S, Seeley W, DeArmond S . Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011; 70(2):327-40. PMC: 3154081. DOI: 10.1002/ana.22424. View

Kales H, Gitlin L, Lyketsos C . Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014; 62(4):762-9. PMC: 4146407. DOI: 10.1111/jgs.12730. View

Gorno-Tempini M, Hillis A, Weintraub S, Kertesz A, Mendez M, Cappa S . Classification of primary progressive aphasia and its variants. Neurology. 2011; 76(11):1006-14. PMC: 3059138. DOI: 10.1212/WNL.0b013e31821103e6. View

Henry M, Hubbard H, Grasso S, Mandelli M, Wilson S, Sathishkumar M . Retraining speech production and fluency in non-fluent/agrammatic primary progressive aphasia. Brain. 2018; 141(6):1799-1814. PMC: 5972572. DOI: 10.1093/brain/awy101. View

Deckers K, van Boxtel M, Schiepers O, de Vugt M, Munoz Sanchez J, Anstey K . Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies. Int J Geriatr Psychiatry. 2014; 30(3):234-46. DOI: 10.1002/gps.4245. View

Casaletto K, Staffaroni A, Wolf A, Appleby B, Brushaber D, Coppola G . Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration. Alzheimers Dement. 2020; 16(1):91-105. PMC: 6953618. DOI: 10.1002/alz.12001. View

10.

Huey E, Putnam K, Grafman J . A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006; 66(1):17-22. PMC: 4499854. DOI: 10.1212/01.wnl.0000191304.55196.4d. View

11.

Engelborghs S, Vloeberghs E, Le Bastard N, Van Buggenhout M, Marien P, Somers N . The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochem Int. 2007; 52(6):1052-60. DOI: 10.1016/j.neuint.2007.10.018. View

12.

Sparks D, Markesbery W . Altered serotonergic and cholinergic synaptic markers in Pick's disease. Arch Neurol. 1991; 48(8):796-9. DOI: 10.1001/archneur.1991.00530200032014. View

13.

Procter A, Qurne M, Francis P . Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord. 1999; 10 Suppl 1:80-4. DOI: 10.1159/000051219. View

14.

Yang Y, Schmitt H . Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation. Immunocytochemical and quantitative study using a graph method. Acta Neuropathol. 2001; 101(3):256-70. DOI: 10.1007/s004010000293. View

15.

Prodan C, Monnot M, Ross E . Behavioural abnormalities associated with rapid deterioration of language functions in semantic dementia respond to sertraline. J Neurol Neurosurg Psychiatry. 2009; 80(12):1416-7. DOI: 10.1136/jnnp.2009.173260. View

16.

Frisoni G, Pizzolato G, Bianchetti A, Chierichetti F, Ferlin G, Battistin L . Single photon emission computed tomography with [99Tc]-HM-PAO and [123I]-IBZM in Alzheimer's disease and dementia of frontal type: preliminary results. Acta Neurol Scand. 1994; 89(3):199-203. DOI: 10.1111/j.1600-0404.1994.tb01661.x. View

17.

Kerssens C, Kerrsens C, Pijnenburg Y . Vulnerability to neuroleptic side effects in frontotemporal dementia. Eur J Neurol. 2008; 15(2):111-2. DOI: 10.1111/j.1468-1331.2007.02035.x. View

18.

Steinberg M, Lyketsos C . Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry. 2012; 169(9):900-6. PMC: 3516138. DOI: 10.1176/appi.ajp.2012.12030342. View

19.

Kales H, Kim H, Zivin K, Valenstein M, Seyfried L, Chiang C . Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2011; 169(1):71-9. PMC: 4269551. DOI: 10.1176/appi.ajp.2011.11030347. View

20.

Weiden P . EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007; 13(1):13-24. DOI: 10.1097/00131746-200701000-00003. View